Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9,598 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer.
Overman MJ, Adam L, Raghav K, Wang J, Kee B, Fogelman D, Eng C, Vilar E, Shroff R, Dasari A, Wolff R, Morris J, Karunasena E, Pisanic TR 2nd, Azad N, Kopetz S. Overman MJ, et al. Among authors: morris j. Ann Oncol. 2018 Jan 1;29(1):139-144. doi: 10.1093/annonc/mdx688. Ann Oncol. 2018. PMID: 29069279 Free PMC article. Clinical Trial.
CpG island methylation in colorectal adenomas.
Rashid A, Shen L, Morris JS, Issa JP, Hamilton SR. Rashid A, et al. Among authors: morris js. Am J Pathol. 2001 Sep;159(3):1129-35. doi: 10.1016/S0002-9440(10)61789-0. Am J Pathol. 2001. PMID: 11549606 Free PMC article.
Concordant CpG island methylation in hyperplastic polyposis.
Chan AO, Issa JP, Morris JS, Hamilton SR, Rashid A. Chan AO, et al. Among authors: morris js. Am J Pathol. 2002 Feb;160(2):529-36. doi: 10.1016/S0002-9440(10)64872-9. Am J Pathol. 2002. PMID: 11839573 Free PMC article.
Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer.
Krishnan S, Janjan NA, Skibber JM, Rodriguez-Bigas MA, Wolff RA, Das P, Delclos ME, Chang GJ, Hoff PM, Eng C, Brown TD, Crane CH, Feig BW, Morris J, Vadhan-Raj S, Hamilton SR, Lin EH. Krishnan S, et al. Among authors: morris j. Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):762-71. doi: 10.1016/j.ijrobp.2006.05.063. Int J Radiat Oncol Biol Phys. 2006. PMID: 17011451 Clinical Trial.
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.
Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, Heymach JV. Kopetz S, et al. Among authors: morris js. J Clin Oncol. 2010 Jan 20;28(3):453-9. doi: 10.1200/JCO.2009.24.8252. Epub 2009 Dec 14. J Clin Oncol. 2010. PMID: 20008624 Free PMC article. Clinical Trial.
Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial.
Fogelman D, Jafari M, Varadhachary GR, Xiong H, Bullock S, Ozer H, Lin E, Morris J, Cunningham P, Bennett B, Abbruzzese JL, Wolff RA. Fogelman D, et al. Among authors: morris j. Cancer Chemother Pharmacol. 2011 Dec;68(6):1431-8. doi: 10.1007/s00280-011-1601-4. Epub 2011 Apr 9. Cancer Chemother Pharmacol. 2011. PMID: 21479635 Clinical Trial.
9,598 results